Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
British Journal of Clinical Pharmacology · 2026
DOI: 10.1111/bcp.15877 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Friederike Thomasius und 2 weiteren Autor:innen. Beteiligte Einrichtung: Frankfurter Hormon & Osteoporosezentrum, Frankfurt, Germany. Hauptthemen laut MEDLINE: Space Flight, Bone Density Conservation Agents, Bone Resorption, Osteoporosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Despite 2 h of daily exercise training, muscle wasting and bone loss are still present after 6‐month missions to the international space station. Some crew members lose bone much faster than others. In preparation for missions to the Moon and Mars, space agencies are therefore reviewing their countermeasure portfolios. Here, we discuss the potential of current pharmacological strategies. Bone loss in space is fuelled by bone resorption. Alendronate, an oral bisphosphonate, reduced bone losses in experimental bed rest and space. However, gastrointestinal side effects precluded its further utilization in space. Zoledronate (a potent bisphosphonate), denosumab (RANKL antagonist) and romosozumab (sclerostin antagonist) are all administered via injection. They effectively suppress bone resorption and are routinely prescribed against osteoporosis. Their serious adverse effects, namely, osteonecrosis of the jaw and atypical femur fractures occur very rarely when the usage is limited to 1 or 2 years. Hence, utilization of one of these compounds may outweigh the bone risks of space travelling, in particular in those with high bone resorption rates. Muscle wasting in space is likely due to hampered muscle protein synthesis. Even though this might theoretically be countered by the synthesis‐boosting effects of anabolic steroids, the practical grounds for such recommendation are currently weak. Moreover, they reveal their full potential only when combined with an anabolic exercise stimulus, for example, via strength training. It therefore seems that a combination of exercise and pharmacological countermeasures should be considered for musculoskeletal health on the way to the Moon and Mars and back.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Frankfurter Hormon & Osteoporosezentrum, Frankfurt, Germany.
- Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany.
- Centre for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, Cologne, Germany.
- Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- Department of Pediatrics and Adolescent Medicine, University Hospital Cologne, Cologne, Germany.
ORCID-Profile: Jörn Rittweger
Zitieren
APA
Thomasius, F., Pesta, D., & Rittweger, J. (2026). Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15877
Vancouver
Thomasius F, Pesta D, Rittweger J. Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions. British Journal of Clinical Pharmacology. 2026. doi:10.1111/bcp.15877
BibTeX
@article{Thomasius2026,
author = {Thomasius, Friederike and Pesta, Dominik and Rittweger, Jörn},
title = {Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1111/bcp.15877}
}
EUVIMED